KUALA LUMPUR, June 16 (Bernama) -- Tessa Therapeutics Ltd (Tessa), a clinical-stage cell therapy company announced promising safety and efficacy data from a study of its off-the-shelf CD30.CAR EBVST therapy (TT11X) in patients with relapsed or refractory (R/R) Hodgkin lymphoma. The results were presented by Tessa collaborators at the Baylor College of Medicine in an oral podium presentation at the 17th International Conference on Malignant Lymphoma (ICML) taking place at Lugano, Switzerland. According to Tessa in a statement, TT11X, its allogeneic 'off-the-shelf' cell therapy, is based on the company's proprietary CD30.

https://www.bernama.com/en/general/news.php?id=2198744

#bernama